Abstract:Farnesoid X receptor (FXR) is a promising target for drug discovery against nonalcoholic fatty liver disease (NAFLD). However, no FXR agonist has been approved for NAFLD so far. The R & D of FXR agonists are somewhat hindered by the lack of effective and safe chemotypes. To this end, we developed a multi-stage computational workflow to screen the Specs and ChemDiv chemical library for FXR agonists, which consisted of machine learning (ML)-based classifiers, shape-based and electrostatic-based models, a FRED-based molecular docking protocol, an ADMET prediction protocol and substructure search. As a result, we identified a novel chemotype that has never been reported before, with compound XJ02862 (ChemDiv ID: Y020-6413) as the representative. By designing an asymmetric synthesis strategy, we were able to prepare four isomers of compound XJ02862. Interestingly, one of the isomers, 2-((S)-1-((2S,4R)-2-methyl-4-(phenylamino)-3,4-dihydroquinolin-1(2H)-yl)-1-oxopropan-2-yl)hexahydro-1H-isoindole-1,3(2H)-dione (XJ02862-S2), showed potent FXR agonistic activity in HEK293T cells. The molecular docking, molecular dynamics simulations and site-directed mutagenesis suggested the hydrogen bond between compound XJ02862-S2 and HIS294 of FXR is essential for ligand binding. We further demonstrated that compound XJ02862-S2 had no agonistic effect on TGR5. Further biological experiments have shown that compound XJ02862-S2 could ameliorate hypercholesterolemia, hepatic steatosis, hyperglycemia, insulin resistance (IR) in high-fat-diet induced obese (DIO) mice. In term of molecular mechanism, compound XJ02862-S2 regulates the expression of FXR downstream genes involved in lipogenesis, cholesterol transport and bile acid biosynthesis and transport. Taken together, we have discovered a novel chemotype as potent FXR agonists for NAFLD by computational modeling, chemical synthesis and biological evaluation.

Design, Synthesis and Biological Activity of Phenoxyacetic Acid Derivatives As Novel Free Fatty Acid Receptor 1 Agonists.

Synthesis and Biological Evaluation of Phenoxyacetic Acid Derivatives As Novel Free Fatty Acid Receptor 1 Agonists.

Design, Synthesis and Structure-Activity Relationship Studies of Novel Phenoxyacetamide-Based Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Design, Synthesis and Structure-Activity Relationship Studies of Novel Free Fatty Acid Receptor 1 Agonists Bearing Amide Linker.

Identification of Highly Potent and Orally Available Free Fatty Acid Receptor 1 Agonists Bearing Isoxazole Scaffold

Discovery of Phenylsulfonyl Acetic Acid Derivatives with Improved Efficacy and Safety As Potent Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes

Design, Synthesis, and Biological Evaluation of Deuterated Phenylpropionic Acid Derivatives As Potent and Long-Acting Free Fatty Acid Receptor 1 Agonists.

Design, Synthesis and Structure-Activity Relationship Studies of New Thiazole-Based Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes

Discovery of Novel Free Fatty Acid Receptor 1 Agonists Bearing Triazole Core Via Click Chemistry

Novel Phenoxyalkanoic Acid Derivatives as Free Fatty Acid Receptor 4 Agonists for Treating Type 2 Diabetes Mellitus

Structure-based Optimization of Free Fatty Acid Receptor 1 Agonists Bearing Thiazole Scaffold.

Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold

Synthesis and evaluation of 3-(4-(phenoxymethyl)phenyl)propanoic acid and N-phenylbenzenesulfonamide derivatives as FFA4 agonists.

Design, Synthesis, and Biological Evaluation of Novel FFA1 Partial Agonists Bearing Oxime Ether Scaffold

Design, Synthesis, and Biological Evaluation of Novel Dual FFA1 (gpr40)/pparδ Agonists As Potential Anti-Diabetic Agents.

Discovery of a novel oxime ether scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists

Design, Synthesis, and Biological Evaluation of Novel Pan Agonists of FFA1, PPARγ and PPARδ.

Discovery of Novel Pyrrole-Based Scaffold As Potent and Orally Bioavailable Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes

Design, Synthesis and Biological Activity of Deuterium-Based FFA1 Agonists with Improved Pharmacokinetic Profiles

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists